nodes	percent_of_prediction	percent_of_DWPC	metapath
Sumatriptan—ABCB1—melanoma	0.223	1	CbGaD
Sumatriptan—ABCG2—Vemurafenib—melanoma	0.173	0.422	CbGbCtD
Sumatriptan—ABCG2—Dactinomycin—melanoma	0.115	0.28	CbGbCtD
Sumatriptan—ABCG2—Docetaxel—melanoma	0.0592	0.145	CbGbCtD
Sumatriptan—ABCB1—Dactinomycin—melanoma	0.0414	0.101	CbGbCtD
Sumatriptan—ABCB1—Docetaxel—melanoma	0.0214	0.0522	CbGbCtD
Sumatriptan—HTR1D—meninx—melanoma	0.017	0.502	CbGeAlD
Sumatriptan—HTR1B—blood vessel—melanoma	0.002	0.0588	CbGeAlD
Sumatriptan—HTR1D—blood vessel—melanoma	0.00193	0.0569	CbGeAlD
Sumatriptan—HTR1F—head—melanoma	0.00147	0.0433	CbGeAlD
Sumatriptan—MAOA—neck—melanoma	0.00105	0.031	CbGeAlD
Sumatriptan—HTR1D—eye—melanoma	0.00103	0.0303	CbGeAlD
Sumatriptan—MAOA—retina—melanoma	0.000776	0.0229	CbGeAlD
Sumatriptan—DRD2—eye—melanoma	0.000775	0.0228	CbGeAlD
Sumatriptan—DRD2—retina—melanoma	0.000768	0.0226	CbGeAlD
Sumatriptan—HTR3A—head—melanoma	0.000719	0.0212	CbGeAlD
Sumatriptan—ABCB1—blood vessel—melanoma	0.000629	0.0185	CbGeAlD
Sumatriptan—MAOA—mammalian vulva—melanoma	0.000621	0.0183	CbGeAlD
Sumatriptan—HTR1B—head—melanoma	0.000603	0.0178	CbGeAlD
Sumatriptan—HTR1D—head—melanoma	0.000584	0.0172	CbGeAlD
Sumatriptan—SLCO1A2—head—melanoma	0.000567	0.0167	CbGeAlD
Sumatriptan—ABCG2—mammalian vulva—melanoma	0.000539	0.0159	CbGeAlD
Sumatriptan—HTR1A—head—melanoma	0.000487	0.0143	CbGeAlD
Sumatriptan—MAOA—head—melanoma	0.000445	0.0131	CbGeAlD
Sumatriptan—DRD2—head—melanoma	0.00044	0.0129	CbGeAlD
Sumatriptan—Melatonin—CYP1B1—melanoma	0.000438	0.752	CrCbGaD
Sumatriptan—Erythema—Bleomycin—melanoma	0.00036	0.00166	CcSEcCtD
Sumatriptan—Hypoaesthesia—Carmustine—melanoma	0.000359	0.00166	CcSEcCtD
Sumatriptan—Hallucination—Carmustine—melanoma	0.000359	0.00166	CcSEcCtD
Sumatriptan—Flushing—Dactinomycin—melanoma	0.000358	0.00165	CcSEcCtD
Sumatriptan—Hypersensitivity—Vemurafenib—melanoma	0.000357	0.00165	CcSEcCtD
Sumatriptan—Connective tissue disorder—Carmustine—melanoma	0.000355	0.00163	CcSEcCtD
Sumatriptan—Visual disturbance—Docetaxel—melanoma	0.000354	0.00163	CcSEcCtD
Sumatriptan—Atrial fibrillation—Docetaxel—melanoma	0.000354	0.00163	CcSEcCtD
Sumatriptan—Dermatitis bullous—Docetaxel—melanoma	0.000351	0.00162	CcSEcCtD
Sumatriptan—Haemoglobin—Temozolomide—melanoma	0.000351	0.00162	CcSEcCtD
Sumatriptan—Haemorrhage—Temozolomide—melanoma	0.000349	0.00161	CcSEcCtD
Sumatriptan—Asthenia—Vemurafenib—melanoma	0.000348	0.0016	CcSEcCtD
Sumatriptan—Visual impairment—Carmustine—melanoma	0.000348	0.0016	CcSEcCtD
Sumatriptan—Hallucination—Temozolomide—melanoma	0.000347	0.0016	CcSEcCtD
Sumatriptan—Hypoaesthesia—Temozolomide—melanoma	0.000347	0.0016	CcSEcCtD
Sumatriptan—Chills—Dactinomycin—melanoma	0.000346	0.00159	CcSEcCtD
Sumatriptan—Pruritus—Vemurafenib—melanoma	0.000343	0.00158	CcSEcCtD
Sumatriptan—Connective tissue disorder—Temozolomide—melanoma	0.000343	0.00158	CcSEcCtD
Sumatriptan—Eye disorder—Carmustine—melanoma	0.000337	0.00155	CcSEcCtD
Sumatriptan—Visual impairment—Temozolomide—melanoma	0.000336	0.00155	CcSEcCtD
Sumatriptan—Erythema—Dactinomycin—melanoma	0.000336	0.00155	CcSEcCtD
Sumatriptan—Gastrointestinal haemorrhage—Docetaxel—melanoma	0.000335	0.00155	CcSEcCtD
Sumatriptan—Flushing—Carmustine—melanoma	0.000335	0.00154	CcSEcCtD
Sumatriptan—Ill-defined disorder—Bleomycin—melanoma	0.000334	0.00154	CcSEcCtD
Sumatriptan—Anaemia—Bleomycin—melanoma	0.000333	0.00153	CcSEcCtD
Sumatriptan—ABCB1—retina—melanoma	0.000332	0.00977	CbGeAlD
Sumatriptan—Diarrhoea—Vemurafenib—melanoma	0.000332	0.00153	CcSEcCtD
Sumatriptan—Migraine—Docetaxel—melanoma	0.00033	0.00152	CcSEcCtD
Sumatriptan—Eye disorder—Temozolomide—melanoma	0.000326	0.0015	CcSEcCtD
Sumatriptan—Tinnitus—Temozolomide—melanoma	0.000325	0.0015	CcSEcCtD
Sumatriptan—Malaise—Bleomycin—melanoma	0.000325	0.0015	CcSEcCtD
Sumatriptan—Flushing—Temozolomide—melanoma	0.000324	0.00149	CcSEcCtD
Sumatriptan—Arrhythmia—Carmustine—melanoma	0.000322	0.00149	CcSEcCtD
Sumatriptan—Dizziness—Vemurafenib—melanoma	0.000321	0.00148	CcSEcCtD
Sumatriptan—Angiopathy—Temozolomide—melanoma	0.000316	0.00146	CcSEcCtD
Sumatriptan—Immune system disorder—Temozolomide—melanoma	0.000315	0.00145	CcSEcCtD
Sumatriptan—Mediastinal disorder—Temozolomide—melanoma	0.000314	0.00145	CcSEcCtD
Sumatriptan—Erythema—Carmustine—melanoma	0.000314	0.00145	CcSEcCtD
Sumatriptan—Cough—Bleomycin—melanoma	0.000314	0.00145	CcSEcCtD
Sumatriptan—Chills—Temozolomide—melanoma	0.000313	0.00144	CcSEcCtD
Sumatriptan—Dehydration—Docetaxel—melanoma	0.000312	0.00144	CcSEcCtD
Sumatriptan—Ill-defined disorder—Dactinomycin—melanoma	0.000311	0.00144	CcSEcCtD
Sumatriptan—MAOA—lymph node—melanoma	0.000311	0.00917	CbGeAlD
Sumatriptan—Anaemia—Dactinomycin—melanoma	0.00031	0.00143	CcSEcCtD
Sumatriptan—Liver function test abnormal—Docetaxel—melanoma	0.00031	0.00143	CcSEcCtD
Sumatriptan—Vomiting—Vemurafenib—melanoma	0.000308	0.00142	CcSEcCtD
Sumatriptan—Myalgia—Bleomycin—melanoma	0.000306	0.00141	CcSEcCtD
Sumatriptan—Chest pain—Bleomycin—melanoma	0.000306	0.00141	CcSEcCtD
Sumatriptan—Rash—Vemurafenib—melanoma	0.000306	0.00141	CcSEcCtD
Sumatriptan—Dermatitis—Vemurafenib—melanoma	0.000305	0.00141	CcSEcCtD
Sumatriptan—Back pain—Carmustine—melanoma	0.000304	0.0014	CcSEcCtD
Sumatriptan—Headache—Vemurafenib—melanoma	0.000304	0.0014	CcSEcCtD
Sumatriptan—Erythema—Temozolomide—melanoma	0.000304	0.0014	CcSEcCtD
Sumatriptan—Discomfort—Bleomycin—melanoma	0.000303	0.0014	CcSEcCtD
Sumatriptan—Malaise—Dactinomycin—melanoma	0.000303	0.0014	CcSEcCtD
Sumatriptan—Cramp muscle—Docetaxel—melanoma	0.000302	0.00139	CcSEcCtD
Sumatriptan—Dysgeusia—Temozolomide—melanoma	0.000297	0.00137	CcSEcCtD
Sumatriptan—Confusional state—Bleomycin—melanoma	0.000296	0.00137	CcSEcCtD
Sumatriptan—Tremor—Carmustine—melanoma	0.000294	0.00136	CcSEcCtD
Sumatriptan—Oedema—Bleomycin—melanoma	0.000294	0.00135	CcSEcCtD
Sumatriptan—Anaphylactic shock—Bleomycin—melanoma	0.000294	0.00135	CcSEcCtD
Sumatriptan—Back pain—Temozolomide—melanoma	0.000294	0.00135	CcSEcCtD
Sumatriptan—Infection—Bleomycin—melanoma	0.000292	0.00135	CcSEcCtD
Sumatriptan—Anaemia—Carmustine—melanoma	0.00029	0.00134	CcSEcCtD
Sumatriptan—Dysphagia—Docetaxel—melanoma	0.00029	0.00134	CcSEcCtD
Sumatriptan—Agitation—Carmustine—melanoma	0.000289	0.00133	CcSEcCtD
Sumatriptan—Nausea—Vemurafenib—melanoma	0.000288	0.00133	CcSEcCtD
Sumatriptan—Thrombocytopenia—Bleomycin—melanoma	0.000288	0.00133	CcSEcCtD
Sumatriptan—Myalgia—Dactinomycin—melanoma	0.000286	0.00132	CcSEcCtD
Sumatriptan—Bronchospasm—Docetaxel—melanoma	0.000285	0.00131	CcSEcCtD
Sumatriptan—Tremor—Temozolomide—melanoma	0.000284	0.00131	CcSEcCtD
Sumatriptan—Discomfort—Dactinomycin—melanoma	0.000282	0.0013	CcSEcCtD
Sumatriptan—Angina pectoris—Docetaxel—melanoma	0.000282	0.0013	CcSEcCtD
Sumatriptan—Ill-defined disorder—Temozolomide—melanoma	0.000282	0.0013	CcSEcCtD
Sumatriptan—Anaemia—Temozolomide—melanoma	0.000281	0.00129	CcSEcCtD
Sumatriptan—Agitation—Temozolomide—melanoma	0.000279	0.00129	CcSEcCtD
Sumatriptan—Angioedema—Temozolomide—melanoma	0.000277	0.00128	CcSEcCtD
Sumatriptan—Pancytopenia—Docetaxel—melanoma	0.000275	0.00127	CcSEcCtD
Sumatriptan—Hypotension—Bleomycin—melanoma	0.000275	0.00127	CcSEcCtD
Sumatriptan—Oedema—Dactinomycin—melanoma	0.000274	0.00126	CcSEcCtD
Sumatriptan—Malaise—Temozolomide—melanoma	0.000274	0.00126	CcSEcCtD
Sumatriptan—Vertigo—Temozolomide—melanoma	0.000273	0.00126	CcSEcCtD
Sumatriptan—Convulsion—Carmustine—melanoma	0.000272	0.00125	CcSEcCtD
Sumatriptan—Infection—Dactinomycin—melanoma	0.000272	0.00125	CcSEcCtD
Sumatriptan—Hypertension—Carmustine—melanoma	0.000271	0.00125	CcSEcCtD
Sumatriptan—ABCG2—lymph node—melanoma	0.00027	0.00795	CbGeAlD
Sumatriptan—Palpitations—Temozolomide—melanoma	0.000268	0.00124	CcSEcCtD
Sumatriptan—Thrombocytopenia—Dactinomycin—melanoma	0.000268	0.00124	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Bleomycin—melanoma	0.000268	0.00123	CcSEcCtD
Sumatriptan—Chest pain—Carmustine—melanoma	0.000268	0.00123	CcSEcCtD
Sumatriptan—Myalgia—Carmustine—melanoma	0.000268	0.00123	CcSEcCtD
Sumatriptan—Anxiety—Carmustine—melanoma	0.000267	0.00123	CcSEcCtD
Sumatriptan—ABCB1—mammalian vulva—melanoma	0.000266	0.00782	CbGeAlD
Sumatriptan—Cough—Temozolomide—melanoma	0.000265	0.00122	CcSEcCtD
Sumatriptan—Paraesthesia—Bleomycin—melanoma	0.000264	0.00122	CcSEcCtD
Sumatriptan—Weight increased—Docetaxel—melanoma	0.000264	0.00122	CcSEcCtD
Sumatriptan—Convulsion—Temozolomide—melanoma	0.000263	0.00121	CcSEcCtD
Sumatriptan—Weight decreased—Docetaxel—melanoma	0.000262	0.00121	CcSEcCtD
Sumatriptan—Hypertension—Temozolomide—melanoma	0.000262	0.00121	CcSEcCtD
Sumatriptan—Dyspnoea—Bleomycin—melanoma	0.000262	0.00121	CcSEcCtD
Sumatriptan—Confusional state—Carmustine—melanoma	0.000259	0.00119	CcSEcCtD
Sumatriptan—Myalgia—Temozolomide—melanoma	0.000259	0.00119	CcSEcCtD
Sumatriptan—Arthralgia—Temozolomide—melanoma	0.000259	0.00119	CcSEcCtD
Sumatriptan—Anxiety—Temozolomide—melanoma	0.000258	0.00119	CcSEcCtD
Sumatriptan—Oedema—Carmustine—melanoma	0.000256	0.00118	CcSEcCtD
Sumatriptan—Discomfort—Temozolomide—melanoma	0.000255	0.00118	CcSEcCtD
Sumatriptan—Decreased appetite—Bleomycin—melanoma	0.000255	0.00118	CcSEcCtD
Sumatriptan—Infection—Carmustine—melanoma	0.000255	0.00117	CcSEcCtD
Sumatriptan—Acute coronary syndrome—Docetaxel—melanoma	0.000255	0.00117	CcSEcCtD
Sumatriptan—Myocardial infarction—Docetaxel—melanoma	0.000253	0.00117	CcSEcCtD
Sumatriptan—Dry mouth—Temozolomide—melanoma	0.000253	0.00117	CcSEcCtD
Sumatriptan—Pain—Bleomycin—melanoma	0.000251	0.00116	CcSEcCtD
Sumatriptan—Conjunctivitis—Docetaxel—melanoma	0.000251	0.00116	CcSEcCtD
Sumatriptan—Thrombocytopenia—Carmustine—melanoma	0.000251	0.00116	CcSEcCtD
Sumatriptan—Tachycardia—Carmustine—melanoma	0.00025	0.00115	CcSEcCtD
Sumatriptan—Confusional state—Temozolomide—melanoma	0.00025	0.00115	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00025	0.00115	CcSEcCtD
Sumatriptan—Oedema—Temozolomide—melanoma	0.000248	0.00114	CcSEcCtD
Sumatriptan—Anaphylactic shock—Temozolomide—melanoma	0.000248	0.00114	CcSEcCtD
Sumatriptan—Infection—Temozolomide—melanoma	0.000246	0.00113	CcSEcCtD
Sumatriptan—Epistaxis—Docetaxel—melanoma	0.000244	0.00112	CcSEcCtD
Sumatriptan—Nervous system disorder—Temozolomide—melanoma	0.000243	0.00112	CcSEcCtD
Sumatriptan—Thrombocytopenia—Temozolomide—melanoma	0.000243	0.00112	CcSEcCtD
Sumatriptan—Feeling abnormal—Bleomycin—melanoma	0.000242	0.00112	CcSEcCtD
Sumatriptan—Skin disorder—Temozolomide—melanoma	0.000241	0.00111	CcSEcCtD
Sumatriptan—Hypotension—Carmustine—melanoma	0.00024	0.0011	CcSEcCtD
Sumatriptan—Hyperhidrosis—Temozolomide—melanoma	0.00024	0.0011	CcSEcCtD
Sumatriptan—Decreased appetite—Dactinomycin—melanoma	0.000238	0.0011	CcSEcCtD
Sumatriptan—Fatigue—Dactinomycin—melanoma	0.000236	0.00109	CcSEcCtD
Sumatriptan—Pain—Dactinomycin—melanoma	0.000234	0.00108	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Carmustine—melanoma	0.000234	0.00108	CcSEcCtD
Sumatriptan—Urticaria—Bleomycin—melanoma	0.000233	0.00108	CcSEcCtD
Sumatriptan—Haemoglobin—Docetaxel—melanoma	0.000233	0.00107	CcSEcCtD
Sumatriptan—Body temperature increased—Bleomycin—melanoma	0.000232	0.00107	CcSEcCtD
Sumatriptan—Haemorrhage—Docetaxel—melanoma	0.000232	0.00107	CcSEcCtD
Sumatriptan—Hypoaesthesia—Docetaxel—melanoma	0.000231	0.00106	CcSEcCtD
Sumatriptan—Paraesthesia—Carmustine—melanoma	0.00023	0.00106	CcSEcCtD
Sumatriptan—Dyspnoea—Carmustine—melanoma	0.000229	0.00105	CcSEcCtD
Sumatriptan—Somnolence—Carmustine—melanoma	0.000228	0.00105	CcSEcCtD
Sumatriptan—Connective tissue disorder—Docetaxel—melanoma	0.000228	0.00105	CcSEcCtD
Sumatriptan—Feeling abnormal—Dactinomycin—melanoma	0.000226	0.00104	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Temozolomide—melanoma	0.000226	0.00104	CcSEcCtD
Sumatriptan—Gastrointestinal pain—Dactinomycin—melanoma	0.000224	0.00103	CcSEcCtD
Sumatriptan—Visual impairment—Docetaxel—melanoma	0.000224	0.00103	CcSEcCtD
Sumatriptan—Decreased appetite—Carmustine—melanoma	0.000223	0.00103	CcSEcCtD
Sumatriptan—Paraesthesia—Temozolomide—melanoma	0.000223	0.00103	CcSEcCtD
Sumatriptan—Gastrointestinal disorder—Carmustine—melanoma	0.000221	0.00102	CcSEcCtD
Sumatriptan—Dyspnoea—Temozolomide—melanoma	0.000221	0.00102	CcSEcCtD
Sumatriptan—Somnolence—Temozolomide—melanoma	0.00022	0.00102	CcSEcCtD
Sumatriptan—Pain—Carmustine—melanoma	0.000219	0.00101	CcSEcCtD
Sumatriptan—Constipation—Carmustine—melanoma	0.000219	0.00101	CcSEcCtD
Sumatriptan—Eye disorder—Docetaxel—melanoma	0.000217	0.000999	CcSEcCtD
Sumatriptan—Body temperature increased—Dactinomycin—melanoma	0.000217	0.000998	CcSEcCtD
Sumatriptan—Abdominal pain—Dactinomycin—melanoma	0.000217	0.000998	CcSEcCtD
Sumatriptan—Hypersensitivity—Bleomycin—melanoma	0.000216	0.000998	CcSEcCtD
Sumatriptan—Decreased appetite—Temozolomide—melanoma	0.000215	0.000993	CcSEcCtD
Sumatriptan—Flushing—Docetaxel—melanoma	0.000215	0.000992	CcSEcCtD
Sumatriptan—Gastrointestinal disorder—Temozolomide—melanoma	0.000214	0.000986	CcSEcCtD
Sumatriptan—Fatigue—Temozolomide—melanoma	0.000214	0.000985	CcSEcCtD
Sumatriptan—Pain—Temozolomide—melanoma	0.000212	0.000977	CcSEcCtD
Sumatriptan—Constipation—Temozolomide—melanoma	0.000212	0.000977	CcSEcCtD
Sumatriptan—Feeling abnormal—Carmustine—melanoma	0.000211	0.000974	CcSEcCtD
Sumatriptan—Asthenia—Bleomycin—melanoma	0.000211	0.000971	CcSEcCtD
Sumatriptan—Angiopathy—Docetaxel—melanoma	0.00021	0.00097	CcSEcCtD
Sumatriptan—Gastrointestinal pain—Carmustine—melanoma	0.00021	0.000966	CcSEcCtD
Sumatriptan—Immune system disorder—Docetaxel—melanoma	0.00021	0.000966	CcSEcCtD
Sumatriptan—Mediastinal disorder—Docetaxel—melanoma	0.000209	0.000963	CcSEcCtD
Sumatriptan—Chills—Docetaxel—melanoma	0.000208	0.000959	CcSEcCtD
Sumatriptan—Pruritus—Bleomycin—melanoma	0.000208	0.000958	CcSEcCtD
Sumatriptan—Arrhythmia—Docetaxel—melanoma	0.000207	0.000955	CcSEcCtD
Sumatriptan—Feeling abnormal—Temozolomide—melanoma	0.000204	0.000941	CcSEcCtD
Sumatriptan—Abdominal pain—Carmustine—melanoma	0.000203	0.000934	CcSEcCtD
Sumatriptan—Body temperature increased—Carmustine—melanoma	0.000203	0.000934	CcSEcCtD
Sumatriptan—Gastrointestinal pain—Temozolomide—melanoma	0.000203	0.000934	CcSEcCtD
Sumatriptan—Erythema—Docetaxel—melanoma	0.000202	0.000931	CcSEcCtD
Sumatriptan—Hypersensitivity—Dactinomycin—melanoma	0.000202	0.00093	CcSEcCtD
Sumatriptan—Dysgeusia—Docetaxel—melanoma	0.000198	0.000911	CcSEcCtD
Sumatriptan—Urticaria—Temozolomide—melanoma	0.000197	0.000907	CcSEcCtD
Sumatriptan—Asthenia—Dactinomycin—melanoma	0.000197	0.000906	CcSEcCtD
Sumatriptan—Abdominal pain—Temozolomide—melanoma	0.000196	0.000903	CcSEcCtD
Sumatriptan—Body temperature increased—Temozolomide—melanoma	0.000196	0.000903	CcSEcCtD
Sumatriptan—Back pain—Docetaxel—melanoma	0.000195	0.0009	CcSEcCtD
Sumatriptan—Muscle spasms—Docetaxel—melanoma	0.000194	0.000895	CcSEcCtD
Sumatriptan—ABCB1—head—melanoma	0.00019	0.0056	CbGeAlD
Sumatriptan—Hypersensitivity—Carmustine—melanoma	0.000189	0.000871	CcSEcCtD
Sumatriptan—Diarrhoea—Dactinomycin—melanoma	0.000187	0.000864	CcSEcCtD
Sumatriptan—Vomiting—Bleomycin—melanoma	0.000187	0.000861	CcSEcCtD
Sumatriptan—Anaemia—Docetaxel—melanoma	0.000187	0.00086	CcSEcCtD
Sumatriptan—Rash—Bleomycin—melanoma	0.000185	0.000854	CcSEcCtD
Sumatriptan—Dermatitis—Bleomycin—melanoma	0.000185	0.000853	CcSEcCtD
Sumatriptan—Asthenia—Carmustine—melanoma	0.000184	0.000848	CcSEcCtD
Sumatriptan—Hypersensitivity—Temozolomide—melanoma	0.000183	0.000841	CcSEcCtD
Sumatriptan—Syncope—Docetaxel—melanoma	0.000181	0.000835	CcSEcCtD
Sumatriptan—Palpitations—Docetaxel—melanoma	0.000178	0.000822	CcSEcCtD
Sumatriptan—Asthenia—Temozolomide—melanoma	0.000178	0.000819	CcSEcCtD
Sumatriptan—Loss of consciousness—Docetaxel—melanoma	0.000177	0.000818	CcSEcCtD
Sumatriptan—Cough—Docetaxel—melanoma	0.000176	0.000812	CcSEcCtD
Sumatriptan—Diarrhoea—Carmustine—melanoma	0.000175	0.000809	CcSEcCtD
Sumatriptan—Pruritus—Temozolomide—melanoma	0.000175	0.000808	CcSEcCtD
Sumatriptan—Convulsion—Docetaxel—melanoma	0.000175	0.000806	CcSEcCtD
Sumatriptan—Nausea—Bleomycin—melanoma	0.000175	0.000804	CcSEcCtD
Sumatriptan—Hypertension—Docetaxel—melanoma	0.000174	0.000803	CcSEcCtD
Sumatriptan—Vomiting—Dactinomycin—melanoma	0.000174	0.000803	CcSEcCtD
Sumatriptan—Rash—Dactinomycin—melanoma	0.000173	0.000796	CcSEcCtD
Sumatriptan—Arthralgia—Docetaxel—melanoma	0.000172	0.000792	CcSEcCtD
Sumatriptan—Chest pain—Docetaxel—melanoma	0.000172	0.000792	CcSEcCtD
Sumatriptan—Myalgia—Docetaxel—melanoma	0.000172	0.000792	CcSEcCtD
Sumatriptan—Dizziness—Carmustine—melanoma	0.00017	0.000782	CcSEcCtD
Sumatriptan—Diarrhoea—Temozolomide—melanoma	0.00017	0.000781	CcSEcCtD
Sumatriptan—Dry mouth—Docetaxel—melanoma	0.000168	0.000775	CcSEcCtD
Sumatriptan—Confusional state—Docetaxel—melanoma	0.000166	0.000766	CcSEcCtD
Sumatriptan—Oedema—Docetaxel—melanoma	0.000165	0.00076	CcSEcCtD
Sumatriptan—Anaphylactic shock—Docetaxel—melanoma	0.000165	0.00076	CcSEcCtD
Sumatriptan—Dizziness—Temozolomide—melanoma	0.000164	0.000755	CcSEcCtD
Sumatriptan—Infection—Docetaxel—melanoma	0.000164	0.000755	CcSEcCtD
Sumatriptan—Vomiting—Carmustine—melanoma	0.000163	0.000751	CcSEcCtD
Sumatriptan—Nausea—Dactinomycin—melanoma	0.000163	0.00075	CcSEcCtD
Sumatriptan—Shock—Docetaxel—melanoma	0.000162	0.000747	CcSEcCtD
Sumatriptan—Rash—Carmustine—melanoma	0.000162	0.000745	CcSEcCtD
Sumatriptan—Nervous system disorder—Docetaxel—melanoma	0.000162	0.000745	CcSEcCtD
Sumatriptan—Dermatitis—Carmustine—melanoma	0.000162	0.000744	CcSEcCtD
Sumatriptan—Thrombocytopenia—Docetaxel—melanoma	0.000161	0.000744	CcSEcCtD
Sumatriptan—Tachycardia—Docetaxel—melanoma	0.000161	0.000741	CcSEcCtD
Sumatriptan—Headache—Carmustine—melanoma	0.000161	0.00074	CcSEcCtD
Sumatriptan—Skin disorder—Docetaxel—melanoma	0.00016	0.000738	CcSEcCtD
Sumatriptan—Vomiting—Temozolomide—melanoma	0.000158	0.000726	CcSEcCtD
Sumatriptan—Rash—Temozolomide—melanoma	0.000156	0.00072	CcSEcCtD
Sumatriptan—Dermatitis—Temozolomide—melanoma	0.000156	0.000719	CcSEcCtD
Sumatriptan—Headache—Temozolomide—melanoma	0.000155	0.000715	CcSEcCtD
Sumatriptan—Hypotension—Docetaxel—melanoma	0.000154	0.00071	CcSEcCtD
Sumatriptan—Nausea—Carmustine—melanoma	0.000152	0.000702	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Docetaxel—melanoma	0.00015	0.000692	CcSEcCtD
Sumatriptan—Paraesthesia—Docetaxel—melanoma	0.000148	0.000682	CcSEcCtD
Sumatriptan—Nausea—Temozolomide—melanoma	0.000147	0.000678	CcSEcCtD
Sumatriptan—Dyspnoea—Docetaxel—melanoma	0.000147	0.000677	CcSEcCtD
Sumatriptan—Somnolence—Docetaxel—melanoma	0.000147	0.000675	CcSEcCtD
Sumatriptan—Eletriptan—ABCB1—melanoma	0.000145	0.249	CrCbGaD
Sumatriptan—Decreased appetite—Docetaxel—melanoma	0.000143	0.00066	CcSEcCtD
Sumatriptan—Gastrointestinal disorder—Docetaxel—melanoma	0.000142	0.000656	CcSEcCtD
Sumatriptan—Fatigue—Docetaxel—melanoma	0.000142	0.000655	CcSEcCtD
Sumatriptan—Pain—Docetaxel—melanoma	0.000141	0.000649	CcSEcCtD
Sumatriptan—Constipation—Docetaxel—melanoma	0.000141	0.000649	CcSEcCtD
Sumatriptan—Feeling abnormal—Docetaxel—melanoma	0.000136	0.000626	CcSEcCtD
Sumatriptan—Gastrointestinal pain—Docetaxel—melanoma	0.000135	0.000621	CcSEcCtD
Sumatriptan—ABCB1—lymph node—melanoma	0.000133	0.00392	CbGeAlD
Sumatriptan—Abdominal pain—Docetaxel—melanoma	0.00013	0.0006	CcSEcCtD
Sumatriptan—Body temperature increased—Docetaxel—melanoma	0.00013	0.0006	CcSEcCtD
Sumatriptan—Hypersensitivity—Docetaxel—melanoma	0.000121	0.00056	CcSEcCtD
Sumatriptan—Asthenia—Docetaxel—melanoma	0.000118	0.000545	CcSEcCtD
Sumatriptan—Pruritus—Docetaxel—melanoma	0.000117	0.000537	CcSEcCtD
Sumatriptan—Diarrhoea—Docetaxel—melanoma	0.000113	0.00052	CcSEcCtD
Sumatriptan—Dizziness—Docetaxel—melanoma	0.000109	0.000502	CcSEcCtD
Sumatriptan—Vomiting—Docetaxel—melanoma	0.000105	0.000483	CcSEcCtD
Sumatriptan—Rash—Docetaxel—melanoma	0.000104	0.000479	CcSEcCtD
Sumatriptan—Dermatitis—Docetaxel—melanoma	0.000104	0.000478	CcSEcCtD
Sumatriptan—Headache—Docetaxel—melanoma	0.000103	0.000476	CcSEcCtD
Sumatriptan—Nausea—Docetaxel—melanoma	9.79e-05	0.000451	CcSEcCtD
Sumatriptan—DRD2—Signaling Pathways—CD86—melanoma	1.08e-05	9.23e-05	CbGpPWpGaD
Sumatriptan—DRD2—GPCR downstream signaling—CXCL8—melanoma	1.08e-05	9.23e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Transmembrane transport of small molecules—ALB—melanoma	1.08e-05	9.22e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—FASN—melanoma	1.07e-05	9.2e-05	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—PIK3CG—melanoma	1.07e-05	9.2e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—IGF1—melanoma	1.07e-05	9.2e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—EDN1—melanoma	1.07e-05	9.16e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—MAPK1—melanoma	1.07e-05	9.16e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—EGFR—melanoma	1.07e-05	9.15e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—IL2—melanoma	1.06e-05	9.12e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—TERT—melanoma	1.06e-05	9.09e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—MAP2K1—melanoma	1.06e-05	9.08e-05	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—MAPK3—melanoma	1.06e-05	9.08e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—RAC1—melanoma	1.06e-05	9.06e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—SLC5A5—melanoma	1.06e-05	9.05e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—PIK3CD—melanoma	1.05e-05	9.02e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CSF2—melanoma	1.04e-05	8.95e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—FGF1—melanoma	1.04e-05	8.95e-05	CbGpPWpGaD
Sumatriptan—HTR1D—GPCR downstream signaling—PIK3CA—melanoma	1.04e-05	8.94e-05	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—PIK3CB—melanoma	1.04e-05	8.91e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—MAP2K1—melanoma	1.04e-05	8.89e-05	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—PPARG—melanoma	1.04e-05	8.88e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—PIK3CD—melanoma	1.03e-05	8.83e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—KRAS—melanoma	1.03e-05	8.83e-05	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—MYC—melanoma	1.03e-05	8.83e-05	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—PTGS2—melanoma	1.03e-05	8.82e-05	CbGpPWpGaD
Sumatriptan—DRD2—GPCR downstream signaling—IL2—melanoma	1.03e-05	8.82e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—E2F1—melanoma	1.02e-05	8.76e-05	CbGpPWpGaD
Sumatriptan—HTR1B—GPCR downstream signaling—PIK3CA—melanoma	1.02e-05	8.75e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—GNAQ—melanoma	1.02e-05	8.74e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—CD44—melanoma	1.02e-05	8.74e-05	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—PIK3CD—melanoma	1.02e-05	8.74e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—PIK3CB—melanoma	1.02e-05	8.72e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—HIF1A—melanoma	1.01e-05	8.69e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—PDGFRA—melanoma	1.01e-05	8.67e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—KRAS—melanoma	1.01e-05	8.65e-05	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—MAPK1—melanoma	1.01e-05	8.64e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—FGF2—melanoma	1.01e-05	8.64e-05	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—EGFR—melanoma	1.01e-05	8.64e-05	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—ALB—melanoma	1.01e-05	8.62e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—PRKCA—melanoma	1e-05	8.58e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—ITGB3—melanoma	1e-05	8.58e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—FGF2—melanoma	9.87e-06	8.46e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—SPP1—melanoma	9.82e-06	8.41e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—MAP2K2—melanoma	9.79e-06	8.39e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—CYP1B1—melanoma	9.78e-06	8.38e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—CXCL8—melanoma	9.77e-06	8.38e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—KDR—melanoma	9.69e-06	8.31e-05	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—PIK3CB—melanoma	9.63e-06	8.25e-05	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—PTGS2—melanoma	9.54e-06	8.18e-05	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—KRAS—melanoma	9.52e-06	8.16e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—PIK3CA—melanoma	9.47e-06	8.11e-05	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—PIK3CD—melanoma	9.44e-06	8.09e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—MDM2—melanoma	9.43e-06	8.08e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—IL2—melanoma	9.34e-06	8.01e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—FN1—melanoma	9.33e-06	8e-05	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—ALB—melanoma	9.32e-06	7.99e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—TERT—melanoma	9.31e-06	7.98e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—ERBB2—melanoma	9.3e-06	7.97e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—RAC1—melanoma	9.28e-06	7.95e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—PIK3CA—melanoma	9.27e-06	7.95e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—MDM2—melanoma	9.23e-06	7.91e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—PIK3CB—melanoma	9.17e-06	7.86e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—NOTCH1—melanoma	9.13e-06	7.83e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—ERBB2—melanoma	9.1e-06	7.8e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—PIK3CB—melanoma	8.98e-06	7.7e-05	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—PTEN—melanoma	8.98e-06	7.7e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CD80—melanoma	8.95e-06	7.67e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—PIK3CG—melanoma	8.93e-06	7.65e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—APC—melanoma	8.93e-06	7.65e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—KIT—melanoma	8.93e-06	7.65e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—NRAS—melanoma	8.93e-06	7.65e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—HIF1A—melanoma	8.9e-06	7.63e-05	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—PIK3CB—melanoma	8.88e-06	7.62e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—EGF—melanoma	8.83e-06	7.57e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CXCL8—melanoma	8.82e-06	7.56e-05	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—PTGS2—melanoma	8.8e-06	7.55e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—HRAS—melanoma	8.76e-06	7.51e-05	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—PIK3CA—melanoma	8.75e-06	7.5e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CXCL8—melanoma	8.63e-06	7.4e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CDKN1B—melanoma	8.61e-06	7.38e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—HRAS—melanoma	8.58e-06	7.35e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—MAPK3—melanoma	8.55e-06	7.33e-05	CbGpPWpGaD
Sumatriptan—HTR1D—GPCR downstream signaling—AKT1—melanoma	8.52e-06	7.3e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—KDR—melanoma	8.51e-06	7.3e-05	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—TP53—melanoma	8.46e-06	7.25e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CASP3—melanoma	8.44e-06	7.23e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CDKN1B—melanoma	8.43e-06	7.23e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—IL2—melanoma	8.42e-06	7.22e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—BRAF—melanoma	8.39e-06	7.2e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—IL6—melanoma	8.38e-06	7.19e-05	CbGpPWpGaD
Sumatriptan—HTR1B—GPCR downstream signaling—AKT1—melanoma	8.34e-06	7.15e-05	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—PTEN—melanoma	8.32e-06	7.13e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CASP3—melanoma	8.26e-06	7.08e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—IL2—melanoma	8.25e-06	7.07e-05	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—PIK3CB—melanoma	8.23e-06	7.05e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CCND1—melanoma	8.21e-06	7.04e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—IL6—melanoma	8.21e-06	7.04e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—FN1—melanoma	8.19e-06	7.02e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—IGF1—melanoma	8.18e-06	7.01e-05	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—PTGS2—melanoma	8.15e-06	6.99e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—MAPK1—melanoma	8.14e-06	6.98e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—EGFR—melanoma	8.14e-06	6.97e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CTNNB1—melanoma	8.13e-06	6.97e-05	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—HRAS—melanoma	8.09e-06	6.94e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CCND1—melanoma	8.04e-06	6.89e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—NOTCH1—melanoma	8.02e-06	6.87e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—MMP9—melanoma	7.97e-06	6.83e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CTNNB1—melanoma	7.96e-06	6.83e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CDKN1A—melanoma	7.95e-06	6.81e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—PTEN—melanoma	7.93e-06	6.79e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—MAP2K1—melanoma	7.9e-06	6.77e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—NFKB1—melanoma	7.89e-06	6.76e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CD80—melanoma	7.85e-06	6.73e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—PIK3CD—melanoma	7.85e-06	6.73e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—KIT—melanoma	7.84e-06	6.72e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—PIK3CG—melanoma	7.84e-06	6.72e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—APC—melanoma	7.84e-06	6.72e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—NRAS—melanoma	7.84e-06	6.72e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—MMP9—melanoma	7.81e-06	6.69e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CDKN1A—melanoma	7.78e-06	6.67e-05	CbGpPWpGaD
Sumatriptan—HTR1A—GPCR downstream signaling—PIK3CA—melanoma	7.78e-06	6.67e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—PTEN—melanoma	7.76e-06	6.65e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—EGF—melanoma	7.75e-06	6.64e-05	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—IL6—melanoma	7.74e-06	6.64e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—AKT1—melanoma	7.73e-06	6.63e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—NFKB1—melanoma	7.72e-06	6.62e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—KRAS—melanoma	7.69e-06	6.59e-05	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—PTEN—melanoma	7.68e-06	6.58e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—AKT1—melanoma	7.57e-06	6.49e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—FGF2—melanoma	7.52e-06	6.44e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—MAPK3—melanoma	7.51e-06	6.44e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—PRKCA—melanoma	7.41e-06	6.35e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—BRAF—melanoma	7.37e-06	6.32e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—ERCC2—melanoma	7.35e-06	6.3e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—IGF1—melanoma	7.18e-06	6.15e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—VEGFA—melanoma	7.16e-06	6.14e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—MAPK1—melanoma	7.14e-06	6.12e-05	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—AKT1—melanoma	7.14e-06	6.12e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—EGFR—melanoma	7.14e-06	6.12e-05	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—PTEN—melanoma	7.11e-06	6.09e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—STAT3—melanoma	7.09e-06	6.08e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—NRAS—melanoma	7.07e-06	6.06e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—PIK3CA—melanoma	7.06e-06	6.05e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—MDM2—melanoma	7.03e-06	6.03e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—VEGFA—melanoma	7.01e-06	6.01e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—STAT3—melanoma	6.94e-06	5.95e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—MAP2K1—melanoma	6.94e-06	5.95e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—ERBB2—melanoma	6.93e-06	5.94e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—NRAS—melanoma	6.92e-06	5.94e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—PIK3CD—melanoma	6.89e-06	5.91e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—PIK3CB—melanoma	6.84e-06	5.87e-05	CbGpPWpGaD
Sumatriptan—DRD2—GPCR downstream signaling—PIK3CA—melanoma	6.83e-06	5.85e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—MAPK3—melanoma	6.77e-06	5.81e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—KRAS—melanoma	6.75e-06	5.78e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—MAPK3—melanoma	6.63e-06	5.68e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—FGF2—melanoma	6.6e-06	5.66e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—MYC—melanoma	6.59e-06	5.65e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CXCL8—melanoma	6.58e-06	5.64e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—HRAS—melanoma	6.53e-06	5.6e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—MYC—melanoma	6.45e-06	5.53e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—MAPK1—melanoma	6.44e-06	5.52e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—EGFR—melanoma	6.44e-06	5.52e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CDKN1B—melanoma	6.42e-06	5.5e-05	CbGpPWpGaD
Sumatriptan—HTR1A—GPCR downstream signaling—AKT1—melanoma	6.35e-06	5.44e-05	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—PIK3CA—melanoma	6.33e-06	5.43e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—MAPK1—melanoma	6.31e-06	5.41e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—EGFR—melanoma	6.31e-06	5.41e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CASP3—melanoma	6.29e-06	5.39e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—IL2—melanoma	6.28e-06	5.39e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—IL6—melanoma	6.25e-06	5.36e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—PIK3CA—melanoma	6.2e-06	5.31e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—MDM2—melanoma	6.17e-06	5.29e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CCND1—melanoma	6.13e-06	5.25e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—ERBB2—melanoma	6.09e-06	5.22e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—KRAS—melanoma	6.09e-06	5.22e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CTNNB1—melanoma	6.07e-06	5.2e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—PIK3CB—melanoma	6.01e-06	5.15e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—KRAS—melanoma	5.96e-06	5.11e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—MMP9—melanoma	5.95e-06	5.1e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CDKN1A—melanoma	5.93e-06	5.08e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—PTEN—melanoma	5.91e-06	5.07e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—NFKB1—melanoma	5.88e-06	5.04e-05	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—PIK3CA—melanoma	5.87e-06	5.03e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—PIK3CG—melanoma	5.8e-06	4.98e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CXCL8—melanoma	5.77e-06	4.95e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—AKT1—melanoma	5.77e-06	4.94e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—HRAS—melanoma	5.74e-06	4.92e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CDKN1B—melanoma	5.64e-06	4.83e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—PPARG—melanoma	5.6e-06	4.8e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—PIK3CA—melanoma	5.59e-06	4.79e-05	CbGpPWpGaD
Sumatriptan—DRD2—GPCR downstream signaling—AKT1—melanoma	5.58e-06	4.78e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CASP3—melanoma	5.53e-06	4.74e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—IL2—melanoma	5.52e-06	4.73e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—IL6—melanoma	5.49e-06	4.71e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—PIK3CA—melanoma	5.48e-06	4.69e-05	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—PIK3CA—melanoma	5.42e-06	4.64e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—TP53—melanoma	5.41e-06	4.64e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CCND1—melanoma	5.38e-06	4.61e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—VEGFA—melanoma	5.34e-06	4.58e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CTNNB1—melanoma	5.33e-06	4.57e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—TP53—melanoma	5.3e-06	4.54e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—STAT3—melanoma	5.29e-06	4.53e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—NRAS—melanoma	5.28e-06	4.52e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—MMP9—melanoma	5.22e-06	4.48e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CDKN1A—melanoma	5.2e-06	4.46e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—PTEN—melanoma	5.19e-06	4.45e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—HRAS—melanoma	5.17e-06	4.43e-05	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—AKT1—melanoma	5.17e-06	4.43e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—NFKB1—melanoma	5.17e-06	4.43e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—PIK3CD—melanoma	5.1e-06	4.37e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—HRAS—melanoma	5.07e-06	4.34e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—AKT1—melanoma	5.06e-06	4.34e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—MAPK3—melanoma	5.05e-06	4.33e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—ALB—melanoma	5.04e-06	4.32e-05	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—PIK3CA—melanoma	5.01e-06	4.3e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—IL6—melanoma	4.95e-06	4.24e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—MYC—melanoma	4.91e-06	4.21e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—IL6—melanoma	4.85e-06	4.16e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—MAPK1—melanoma	4.81e-06	4.12e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—EGFR—melanoma	4.81e-06	4.12e-05	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—AKT1—melanoma	4.79e-06	4.11e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—VEGFA—melanoma	4.69e-06	4.02e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—STAT3—melanoma	4.64e-06	3.98e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—NRAS—melanoma	4.63e-06	3.97e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—AKT1—melanoma	4.57e-06	3.92e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—KRAS—melanoma	4.54e-06	3.89e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—AKT1—melanoma	4.47e-06	3.83e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—PIK3CB—melanoma	4.45e-06	3.81e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—MAPK3—melanoma	4.44e-06	3.8e-05	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—AKT1—melanoma	4.42e-06	3.79e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—PTGS2—melanoma	4.41e-06	3.78e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—MYC—melanoma	4.31e-06	3.7e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—MAPK1—melanoma	4.22e-06	3.62e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—EGFR—melanoma	4.22e-06	3.62e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—PIK3CA—melanoma	4.17e-06	3.58e-05	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—AKT1—melanoma	4.1e-06	3.51e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—TP53—melanoma	4.04e-06	3.46e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—KRAS—melanoma	3.99e-06	3.42e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—HRAS—melanoma	3.86e-06	3.31e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—PTEN—melanoma	3.84e-06	3.29e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—IL6—melanoma	3.69e-06	3.17e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—PIK3CA—melanoma	3.66e-06	3.14e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—TP53—melanoma	3.54e-06	3.04e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—AKT1—melanoma	3.41e-06	2.92e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—HRAS—melanoma	3.39e-06	2.9e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—IL6—melanoma	3.24e-06	2.78e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—AKT1—melanoma	2.99e-06	2.56e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—PIK3CA—melanoma	2.71e-06	2.32e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—AKT1—melanoma	2.21e-06	1.9e-05	CbGpPWpGaD
